This category only includes cookies that ensures basic functionalities and security features of the website. Coughlin received a bachelor’s degree in accounting from Boston College.We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. He joined ARCH at its founding and played a significant role in the early sourcing, financing and development of more than 100 companies, including nineteen which have reached valuations exceeding $1 billion. Steph started her HR/recruiting career in executive search, working with higher education, financial services, and life sciences clients.Stephanie earned her M.A. Always Enabled United StatesKaruna Therapeutics to Present at Upcoming Investor ConferencesKaruna Therapeutics and PsychoGenics Announce Drug Discovery CollaborationKaruna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of AcuteKaruna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceKaruna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis inKaruna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business UpdateKaruna Therapeutics Appoints Christopher J. Coughlin to its Board of DirectorsKaruna Therapeutics to Participate in Stifel’s 2nd Annual CNS Day Virtual EventKaruna Therapeutics Reports Fourth Quarter and Year End 2019 Financial Results and Provides General Business UpdateKaruna Therapeutics to Present at the Cowen and Company's 40th Annual Health Care Conference Dr. Tamminga was elected to the Institute of Medicine of the National Academies of Sciences in 1998 and has served on several IOM committees in that capacity.Improving life for people living with schizophrenia, Alzheimer's disease and pain, and their families.Necessary cookies are absolutely essential for the website to function properly.
You also have the option to opt-out of these cookies but opting out may have an effect on your browsing experience. The Institute’s mission is to assist in the rapid translation of new discoveries into novel treatments.In addition to his roles with the Indiana CTSI and IU School of Medicine, Dr. Shekhar is the Associate Vice President for University Affairs, Indiana University; Executive Vice President of Academic Affairs for Clinical Research, IU Health.Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School; Chairman of the Department of Psychiatry; Chief of the Translational Neuroscience Division in Schizophrenia at UT Southwestern Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School; Chairman of the Department of Psychiatry; Chief of the Translational Neuroscience Division in Schizophrenia at UT Southwestern Dr. Tamminga holds the Lou and Ellen McGinley Distinguished Chair and the McKenzie Chair in Psychiatry at the University of Texas Southwestern Medical School and is the Chairman of the Department of Psychiatry and the Chief of the Translational Neuroscience Division in Schizophrenia at UT Southwestern.
He joined Eli Lilly and Company in 1987 (NYSE: LLY) where he enjoyed a long and successful career, rising to the level of distinguished Lilly scholar. Currency in USDThe pillar scores are Audit: 1; Board: 10; Shareholder Rights: 8; Compensation: 9.Scores indicate decile rank relative to index or region. Dr. Kaul is an experienced global drug development leader with track record of success in regulatory project achievement worldwide, portfolio governance, translational science and commercialization support including medical affairs, life-cycle management, in-licensing and out-licensing evaluations. Potter left the NIH in 1996 to accept a position as Executive Director for early clinical neuroscience at Lilly Research Labs, and in 2004 he joined Merck Research Labs (MRL) as Vice President of Clinical Neuroscience, then moved to the newly created position of Translational Neuroscience in 2006, a position from which he retired in January of 2011.
Prior to this, between December 2002 and December 2015 she worked for GlaxoSmithKline (GSK) in a number of drug development and operational roles. She served on the University of Chicago faculty from 1975 to 1979 and moved to the National Institute for Neurological Disorders and Stroke for training in Neurology in 1978.
It is mandatory to procure user consent prior to running these cookies on your website. In 2012 Xconomy named him one the leading “Young and Proven Biotech VC’s”. from the University of Rochester in Film Studies and B.A. ADDRESS. Dr. Attardo received his Ph.D. from McGill University in 1991.
His many roles included leading discovery research teams, Director of Neuroscience in US and UK sites, strategic and technical committee oversight, external search and evaluate roles and Director of the Lilly Post Doc Program. Jeff’s approach is shaped by a career that encompasses one-on-one patient care, rapid advancement through corporate structures, academic accomplishments, and entrepreneurial endeavors.